Expression of Paxillin in Benign and Malignant Salivary Gland Tumors

AndisheTadbir, Azadeh; Afshari, Aysuda; Ashraf, Mohammad Javad

doi:10.30476/dentjods.2019.44909

Expression of Paxillin in Benign and Malignant Salivary Gland Tumors

Document Type : Original Article

Authors

Azadeh AndisheTadbir ¹

Aysuda Afshari ²

Mohammad Javad Ashraf ³

¹ Oral and Dental Disease Research Center, Dept. of Oral and Maxillofacial Pathology, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran.

² Undergraduate Student, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran.

³ Dept. of Pathology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.

https://doi.org/10.30476/dentjods.2019.44909

Abstract

Statement of the Problem: Paxillin is a major cytoskeletal protein aberrantly deregulated in various human cancers and involved in tumor growth and invasion. However, the clinicopathological and prognostic significance of paxillin in salivary gland tumors (SGTs) is still unclear.
Purpose: This study was conducted to evaluate the relationship between paxillin expression and clinicopathological features of patients with SGTs.
Materials and Method: In this retrospective study, 50 paraffin-embedded tissue samples which were histologically confirmed as benign (pleomorphic adenoma, PA) or malignant (mucoepidermoid carcinoma (MEC), adenoid cystic carcinoma, ACC) SGTs, and 19 specimens from those with normal salivary gland (NSG) as a control group were assessed for paxillin expression using the immunohistochemistry. The paxillin expression in our samples was scored based on the extent and intensity of immunoreactivity and compared with histological type, clinical stage, and distant metastasis.
Results: High paxillin expression was identified in 66% of SGTs whereas all patients with NSG showed low expression (p < 0.0001). Although the expression of paxillin in patients with benign and malignant tumors is similar, there is a significant difference between patients with PA, MEC, and ACC with that of the NSG (p < 0.0001). Paxillin expression was not correlated with clinicopathological features of patients
Conclusion: High expression of paxillin was observed in tumoral tissues compared with the controls that establish an important role of paxillin in SGTs but its prognostic role was unclear and need further evaluation.

Keywords

● Mucoepidermoid Carcinoma ● Paxillin ● Pleomorphic Adenoma ● Immunohistochemistry

. Melo GM, Cervantes O, Abrahao M, Covolan L, Ferreira ES, Baptista HA. A brief history of salivary gland surgery. Rev Col Bras Cir. 2017; 44: 403–412. [PubMed] [Google Scholar]

2. Randy Todd D. The Molecular Biology of Benign and Malignant Salivary Gland Tumors. Salivary Gland Pathology: Diagnosis and Management. 2nd ed . USA: Wiely ; 2015. pp. 203–232. [Google Scholar]

3. Wang X, Luo Y, Li M, Yan H, Sun M, Fan T. Management of salivary gland carcinomas - a review. Oncotarget. 2017; 8: 3946–3956. [PMC free article] [PubMed] [Google Scholar]

4. Peravali RK, Bhat HH, Upadya VH, Agarwal A, Naag S. Salivary gland tumors: a diagnostic dilemma! . J Maxillofac Oral Surg. 2015;( 14(Suppl 1)):438–442. [PMC free article] [PubMed] [Google Scholar]

5. Ettl T, Schwarz-Furlan S, Gosau M, Reichert TE. Salivary gland carcinomas. Oral Maxillofac Surg. 2012; 16: 267–283. [PubMed] [Google Scholar]

6. Chen DL, Wang ZQ, Ren C, Zeng ZL, Wang DS, Luo HY, et al. Abnormal expression of paxillin correlates with tumor progression and poor survival in patients with gastric cancer. J Transl Med. 2013; 11: 277. [PMC free article] [PubMed] [Google Scholar]

7. Xiao LJ, Zhao EH, Zhao S, Zheng X, Zheng HC, Takano Y, et al. Paxillin expression is closely linked to the pathogenesis, progression and prognosis of gastric carcinomas. Oncol Lett. 2014; 7: 189–194. [PMC free article] [PubMed] [Google Scholar]

8. Du C, Wang X, Zhang J, Liu X, Zhu J, Liu Y. Paxillin is positively correlated with the clinicopathological factors of colorectal cancer, and knockdown of Paxillin improves sensitivity to cetuximab in colorectal cancer cells. Oncol Rep. 2016; 35: 409–417. [PubMed] [Google Scholar]

9. Chen DL, Wang DS, Wu WJ, Zeng ZL, Luo HY, Qiu MZ, et al. Overexpression of paxillin induced by miR-137 suppression promotes tumor progression and metastasis in colorectal cancer. Carcinogenesis. 2013; 34: 803–811. [PMC free article] [PubMed] [Google Scholar]

10. Wozniak MA, Modzelewska K, Kwong L, Keely PJ. Focal adhesion regulation of cell behavior. Biochim Biophys Acta. 2004; 1692: 103–119. [PubMed] [Google Scholar]

11. Wu DW, Chuang CY, Lin WL, Sung WW, Cheng YW, Lee H. Paxillin promotes tumor progression and predicts survival and relapse in oral cavity squamous cell carcinoma by microRNA-218 targeting. Carcinogenesis. 2014; 35: 1823–1829. [PubMed] [Google Scholar]

12. Li BZ, Lei W, Zhang CY, Zhou F, Li N, Shi SS, et al. Increased expression of paxillin is found in human oesophageal squamous cell carcinoma: a tissue microarray study. J Int Med Res. 2008; 36: 273–278. [PubMed] [Google Scholar]

13. Jagadeeswaran R, Surawska H, Krishnaswamy S, Janamanchi V, Mackinnon AC, Seiwert TY, et al. Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion. Cancer Res. 2008; 68: 132–142. [PMC free article] [PubMed] [Google Scholar]

14. Wu DW, Cheng YW, Wang J, Chen CY, Lee H. Paxillin predicts survival and relapse in non-small cell lung cancer by microRNA-218 targeting. Cancer Res. 2010; 70: 10392–10401. [PubMed] [Google Scholar]

15. Short SM, Yoder BJ, Tarr SM, Prescott NL, Laniauskas S, Coleman KA, et al. The expression of the cytoskeletal focal adhesion protein paxillin in breast cancercorrelates with HER2 overexpression and may help predict response to chemotherapy: a retrospective immunohistochemical study. Breast J. 2007; 13: 130–139. [PubMed] [Google Scholar]

16. McCormack SJ, Brazinski SE, Moore JL Jr, Werness BA, Goldstein DJ. Activation of the focal adhesion kinase signal transduction pathway in cervicalcarcinoma cell lines and human genital epithelial cells immortalized with humanpapillomavirus type 18. Oncogene. 1997; 15: 265–274. [PubMed] [Google Scholar]

17. Kasai M, Guerrero-Santoro J, Friedman R, Leman ES, Getzenberg RH, DeFranco DB. The Group 3 LIM domain protein paxillin potentiates androgen receptor transactivation in prostate cancer cell lines. Cancer Res. 2003; 63: 4927–4935. [PubMed] [Google Scholar]

18. Sen A, De Castro I, Defranco DB, Deng FM, Melamed J, Kapur P, et al. Paxillin mediates extranuclear and intranuclear signaling in prostate cancer proliferation. J Clin Invest. 2012; 122: 2469–2481. [PMC free article] [PubMed] [Google Scholar]

19. Yin H, Zhang Q, Wang X, Li T, Wan Y, Liu Y, et al. Role of paxillin in colorectal carcinoma and its relationship to clinicopathological features. Chin Med J (Engl) 2014; 127: 423–429. [PubMed] [Google Scholar]

20. Li L, Wang J, Gao L, Gong L. Expression of paxillin in laryngeal squamous cell carcinoma and its prognostic value. Int J Clin Exp Pathol. 2015; 8:9232–9239. [PMC free article] [PubMed] [Google Scholar]

21. Sun LH, Yang FQ, Zhang CB, Wu YP, Liang JS, Jin S, et al. Overexpression of Paxillin Correlates with Tumor Progression and Predicts PoorSurvival in Glioblastoma. CNS Neurosci Ther. 2017; 23: 69–75. [PMC free article] [PubMed] [Google Scholar]

22. Shi J, Wang S, Zhao E, Shi L, Xu X, Fang M. Paxillin expression levels are correlated with clinical stage and metastasis in salivaryadenoid cystic carcinoma. J Oral Pathol Med. 2010; 39: 548–551. [PubMed] [Google Scholar]

23. Turner CE. Paxillin and focal adhesion signalling. Nat Cell Biol. 2000; 2: E231–E236. [PubMed] [Google Scholar]

24. Metalli D, Lovat F, Tripodi F, Genua M, Xu SQ, Spinelli M, et al. The insulin-like growth factor receptor I promotes motility and invasion of bladder cancer cells through Akt- and mitogen-activated protein kinase-dependent activation of paxillin. Am J Pathol. 2010; 176: 2997–3006. [PMC free article] [PubMed] [Google Scholar]

25. Cai HX, Yang LC, Song XH, Liu ZR, Chen YB, Dong GK. Expression of paxillin and FAK mRNA and the related clinical significance in esophagealcarcinoma. Mol Med Rep. 2012; 5: 469–472. [PubMed] [Google Scholar]

26. Li HG, Xie DR, Shen XM, Li HH, Zeng H, Zeng YJ. Clinicopathological significance of expression of paxillin, syndecan-1 and EMMPRIN in hepatocellular carcinoma. World J Gastroenterol. 2005; 11: 1445–1451. [PMC free article] [PubMed] [Google Scholar]

27. Taghavi N, Sargolzaei S, Mashhadiabbas F, Akbarzadeh A, Kardouni P. Salivary Gland Tumors: A 15- year Report from Iran. Turk Patoloji Derg. 2016; 32: 35–39. [PubMed] [Google Scholar]

28. Jaafari-Ashkavandi Z, Ashraf MJ, Moshaverinia M. Salivary gland tumors: a clinicopathologic study of 366 cases in southern Iran. Asian Pac J Cancer Prev. 2013; 14: 27–30. [PubMed] [Google Scholar]

29. Shahsavari F, Khaniki M, Farbod M. Prevalence of Salivary Glands Lesions in Iran: A 10-Year Retrospective Study. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014; 119: e174. [Google Scholar]

30. Athanasopoulou A, Aroukatos P, Nakas D, Repanti M, Papadaki H, Bravou V. Decreased ezrin and paxillin expression in human urothelial bladder tumors correlate with tumor progression. Urol Oncol. 2013;31:836–42. [PubMed] [Google Scholar]

31. Zhao CJ, Du SK, Dang XB, Gong M. Expression of paxillin is correlated with clinical prognosis in colorectal cancer patients. Med Sci Monit. 2015; 21:1989–1995. [PMC free article] [PubMed] [Google Scholar]

32. Zheng QS, Chen SH, Wu YP, Chen HJ, Chen H, Wei Y, et al. Increased Paxillin expression in prostate cancer is associated with advancedpathological features, lymph node metastases and biochemical recurrence. J Cancer. 2018; 9: 959–967. [PMC free article] [PubMed] [Google Scholar]